Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.77 |
| ▸ | MMP12 | P39900 | 18/20 | 0.77 |
| ▸ | MMP9 | P14780 | 17/20 | 0.77 |
| ▸ | MMP8 | P22894 | 14/20 | 0.77 |
| ▸ | MMP13 | P45452 | 14/20 | 0.77 |
| ▸ | MMP14 | P50281 | 13/20 | 0.77 |
| ▸ | MMP16 | P51512 | 13/20 | 0.77 |
| ▸ | MMP3 | P08254 | 11/20 | 0.77 |
| ▸ | MMP1 | P03956 | 6/20 | 0.77 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316169 | 0.93 | MMP2 (0.77) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL314397 | 0.80 | MMP2 (1.00) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL315445 | 0.77 | MMP2 (0.67) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL314725 | 0.75 | MMP2 (0.74) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL316301 | 0.72 | MMP2 (0.87) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL8228874 | 0.72 | MMP2 (1.00) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL10049385 | 0.72 | MMP2 (0.73) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL325258 | 0.71 | MMP2 (1.00) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL10592283 | 0.70 | GAA (0.61) | MMP2MMP12MMP9MMP8MMP13 | |
| SCHEMBL2169790 | 0.70 | CTSD (0.62) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093386-B2 | Thioaryl substituted inhibitors of zinc proteases and their use | BRACCO IMAGING S.P.A (IT) | 2012-01-10 | — | — | US | claimed |
| JP-2009545556-A | — | — | 2009-12-24 | — | — | JP | claimed |
| US-20090239829-A1 | THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE | BRACCO IMAGING SPA (IT) | 2009-09-24 | — | — | US | claimed |
| EP-2059500-A2 | INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE | Bracco Imaging S.p.A (IT) | 2009-05-20 | — | — | EP | claimed |
| WO-2008015139-A2 | INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE | BRACCO IMAGING SPA (IT) | 2008-02-07 | — | — | WO | claimed |
| US-8093386-B2 | Thioaryl substituted inhibitors of zinc proteases and their use | BRACCO IMAGING S.P.A (IT) | 2012-01-10 | — | — | US | disclosed |
| US-20090239829-A1 | THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE | BRACCO IMAGING SPA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-2059500-A2 | INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE | Bracco Imaging S.p.A (IT) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008015139-A2 | INHIBITORS OF ZINC PROTEASES THIOARYL SUBSTITUTED AND THEIR USE | BRACCO IMAGING SPA (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239829-A1 | THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE | SERPINB1, ZFX, MMP2 | MMP2 3/4885MMP12 37/4885MMP9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.